{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:59:36Z","timestamp":1753891176220,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent studies have shown that immunotherapy improves survival outcomes for patients with a late staged cancer. However, in a small number of cases do not benefit from this treatment and instead experience rapid tumor progression, known as hyperprogressive disease (HPD). Currently, HPD is provisionally defined as occurring within two months of receiving immunotherapy. Is HPD that occurs after two months associated with immunotherapy? The existing literature does not provide an answer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 59-year-old woman was diagnosed with unresectable squamous cell carcinoma of the lung. She received four months (6 cycles) of chemotherapy with albumin-bound paclitaxel and cisplatin, along with immunotherapy using Camrelizumab. After treatment, the lesion in the patient\u2019s lung were significantly reduced. However, because the tumor did not disappear and due to the limitations dose of the chemotherapy drugs using for body, the patient turned to receive stereotactic radiation therapy (2 Gy per fraction). After 10 fractions of radiotherapy, the lesion in the patient\u2019s lung significantly increased. The enlarged lesion was pathologically analyzed through a percutaneous lung biopsy and was confirmed to be squamous cell carcinoma. Following the cessation of radiotherapy, four cycles of targeted segment arterial chemoembolization resulted in another significant reduction in the lung lesion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This report is the first to present HPD after 5 months of immunotherapy, marking the longest recorded occurrence of this phenomenon. This particular case of post-immunotherapy HPD achieved satisfactory results through targeted segment arterial chemoembolization, offering a potential approach for managing this side effect.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1552547","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:25:24Z","timestamp":1744867524000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Xia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Ping","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.939873","article-title":"Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074906","article-title":"Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874932","article-title":"Case report: A programmed cell death-1 inhibitor-related abdominal fibroinflammatory reaction affecting multiple organs in A non-small-cell lung cancer patient","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200875","article-title":"Hyperprogressive disease in non-small cell lung cancer after PD-1\/PD-L1 inhibitors immunotherapy: underlying killer","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13594","article-title":"Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Choi","year":"2020","journal-title":"Thorac Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02716-3","article-title":"Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma","volume":"70","author":"Schuiveling","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S367978","article-title":"Cancer metastases from lung adenocarcinoma disappeared after molecular targeted therapy: A successfully clinical treatment experience","volume":"15","author":"Li","year":"2022","journal-title":"Pharmgenomics Pers Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922076","article-title":"Case report: recombinant human\u00a0endostatin plus chemotherapy for treating epidermal growth factor receptor-negative miliary lung adenocarcinoma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566297","article-title":"Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy","volume":"10","author":"Humbert","year":"2020","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.32604\/oncologie.2022.022436","article-title":"Surgery combined with molecular targeted therapy successfully treated giant esophageal gastrointestinal stromal tumor","volume":"24","author":"Li","year":"2022","journal-title":"Oncologie"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096877","article-title":"Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade","volume":"14","author":"Guan","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13073-019-0661-7","article-title":"The good, the bad, and the ugly: hyperprogression in cancer\u00a0patients following immune checkpoint therapy","volume":"11","author":"Sabio","year":"2019","journal-title":"Genome Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccell.2022.12.008","article-title":"Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury: assessment and management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092218","article-title":"Analysis of the causes of solitary pulmonary nodule misdiagnosed as lung cancer by using artificial intelligence: A retrospective study at a single center","volume":"12","author":"Wu","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2020.06.007","article-title":"Combination of bronchial arterial infusion chemotherapy plus drug-eluting embolic transarterial chemoembolization for treatment of advanced lung cancer-A retrospective analysis of 23 patients","volume":"31","author":"Zeng","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000522456","article-title":"Efficacy and safety of super-selective bronchial arterial infusion chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"67","author":"Men","year":"2022","journal-title":"Chemotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1552547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:25:25Z","timestamp":1744867525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1552547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2025.1552547"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1552547","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"article-number":"1552547"}}